Posted by Michael Wonder on 04 Sep 2021
NICE recommends Novartis’ Cosentyx for children with severe psoriasis
3 September 2021 - NICE has recommended Novartis’ interleukin-17A inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.
Specifically, NICE has cleared Cosentyx for people aged six to 17 years old with moderate-to-severe psoriasis who have not responded to other forms of systemic treatment, or where these options were contraindicated or not tolerated.
